2 hrs ago
Godavari Biorefineries Shares Rally After Chinese Patent Grant
Godavari Biorefineries received a patent from China for compounds that may help make medicines for viral infections.
After the news, the company’s shares rose sharply during Wednesday’s trading.
The shares reached ₹258.87, which was a gain of up to 13%.
The patent certificate says it was granted on September 15, 2026.
The company also recently received a patent in Japan for an invention related to cancer treatment.
However, the company’s loss grew during the latest quarter.
Its income increased, but its operating profit measure called EBITDA fell.
Investors are weighing the promise of the patents against the company’s weaker recent financial results.
Godavari Biorefineries shares rose as much as 13% to ₹258.87 on NSE.
The Chinese patent covers V-ATPase-inhibiting compounds and their use in medicines for viral infections.
The patent certificate says the grant was issued on September 15, 2026, under patent number ZL 2021 8 0048053.9.
Godavari Biorefineries reported a wider Q1 FY27 loss of ₹19.3 crore, while total income increased to ₹559.9 crore.
The stock gained 3.16% in one week but remained down 14.78% year to date and 16.62% over one year.
- Who
- Godavari Biorefineries and its named inventors; investors traded the company’s shares.
- What
- The company received a Chinese patent covering V-ATPase-inhibiting compounds and their use in medicines for viral infections, prompting a sharp share-price rise.
- Where
- The shares traded on the NSE, and the patent was granted by the Chinese Patent Office.
- When
- The shares rallied during Wednesday’s trading session; the Chinese patent certificate states that the patent was granted on September 15, 2026.
- Why
- The share-price rise followed the company’s announcement of the Chinese patent grant, although recent quarterly profitability was weaker.
Patent-driven optimism
Financial-performance caution
Investor reaction
Patent-driven optimism
The Chinese patent, which concerns compounds and potential medicines for viral infections, was followed by a share-price rally of as much as 13%.
Financial-performance caution
The rally occurred despite the stock remaining lower over one month, year to date and the past year.
Company outlook
Patent-driven optimism
Godavari Biorefineries has secured a Chinese patent and a recent Japanese patent related to cancer treatment, expanding its reported intellectual-property portfolio.
Financial-performance caution
The company’s Q1 FY27 loss widened, while EBITDA declined from the year-ago quarter.
Key facts
- Intraday share move
- Shares rose as much as 13% to ₹258.87 on NSE.
- Chinese patent
- Patent number ZL 2021 8 0048053.9; publication number CN 115867276 B.
- Patent application
- Filed on May 10, 2021.
- Q1 FY27 loss
- ₹19.3 crore, compared with ₹16 crore in Q1 FY26.
- Q1 FY27 total income
- ₹559.9 crore, compared with ₹534 crore in the year-ago quarter.
- Q1 FY27 EBITDA
- ₹2.6 crore, down from ₹6.5 crore in Q1 FY26.
- Recent stock performance
- Up 3.16% over one week, down 0.51% over one month, 14.78% year to date and 16.62% over one year.
Sources
Related news
Godavari Biorefineries secures European patent for anti-cancer drug composition
Molbio Diagnostics Shares Hit Upper Circuit After Strong IPO Rally
Neogen Shares Fall as QIP Floor Price Set
Molbio Diagnostics Shares Fall After Strong Post-Listing Rally
Indian stocks in focus after orders, approvals and regulatory updates
Robert Kiyosaki Warns Historic Market Crash Has Begun
India Blocks Football Teams From 2026 Asian Games
India Women Arrive in Japan Seeking Asian Games Gold
Pant’s ODI Return Dominates India’s West Indies Squad Selection
